One BioMed Pte Ltd

One BioMed Pte Ltd specializes in advanced molecular solutions, offering innovative technologies for automated nucleic acid extraction. Their flagship product, Xceler8™ Solution, streamlines molecular testing for biomedical research and clinical applications. Founded in 2015 in Singapore, One BioMed Pte Ltd focuses on developing automated molecular platforms. The company was established by Mi-Kyoung Park, who has a history of entrepreneurial endeavors.

As of October 2021, One BioMed raised USD 500,000 in Series A funding, valuing the company at USD 16 million post-money. The firm has successfully completed four deals by this date. One BioMed's primary offering is the integrated Xceler8™ Solution, a state-of-the-art molecular platform designed for automated nucleic acid extraction and purification. This innovative technology employs a patented reversible-crosslinking method, allowing for efficient and selective capture and release of nucleic acids from various biological samples.

The Xceler8 Solution is geared towards both research and clinical applications, enabling biomedical researchers and clinicians to perform advanced nucleic acid extraction with minimal manual intervention. By providing a truly walk-away solution, One BioMed addresses the increasing demand for high-throughput molecular testing across diverse fields, including genomics and diagnostics. The Xceler8 platform is marketed primarily to research institutions, hospitals, and laboratories in regions such as North America, Europe, and Asia, enhancing accessibility to sophisticated molecular tools for a wide array of end users. One BioMed generated revenue of USD 13,805.

50 in 2022, with an EBITDA amount of USD -2,628,601. 40 for the same year. The company generates revenue primarily through direct sales of its Xceler8™ Solution to biomedical researchers and clinical laboratories, likely involving structured transactions that include partnerships and direct sales agreements. In October 2021, One BioMed Pte Ltd raised USD 500,000 in Series A funding from new investor BK Electronics.

This funding will support the development of new products and expansion into targeted markets. Specific regions for growth include further penetration within Asia and Europe, with plans to establish a stronger presence by 2023. The capital raised will assist in increasing production capabilities and expanding the marketing reach of the Xceler8™ Solution, enabling One BioMed to meet the growing demand in the molecular life sciences sector.